搜索
ss
ss
关于普米斯
About Us
s12

Tao Huang (Director)

VP of IDG Capital. Tao has fifteen years’ experience in biomedical research and drug R&D, specialized in R&D technology risk evaluation. Previously served in Novo Nordisk Research Center. He established the drug discovery platform, and participated in over 30 global early-stage pipeline projects in diseases areas such as diabetes, obesity, hemophilia, growth disorders and autoimmune diseases, and was also involved in the evaluation of over 10 external joint projects. Tao holds a post-doctorate degree in Cancer Research Institute, National Institutes of Health (NIH) USA, a PhD degree in Biochemistry from University of Texas Health Science Center at San Antonio and a Bachelor’s degree in Applied Chemistry from University of Science and Technology of China.
s12
Product description
Parameters

VP of IDG Capital. Tao has fifteen years’ experience in biomedical research and drug R&D, specialized in R&D technology risk evaluation. Previously served in Novo Nordisk Research Center. He established the drug discovery platform, and participated in over 30 global early-stage pipeline projects in diseases areas such as diabetes, obesity, hemophilia, growth disorders and autoimmune diseases, and was also involved in the evaluation of over 10 external joint projects. Tao holds a post-doctorate degree in Cancer Research Institute, National Institutes of Health (NIH) USA, a PhD degree in Biochemistry from University of Texas Health Science Center at San Antonio and a Bachelor’s degree in Applied Chemistry from University of Science and Technology of China.

Keyword:
lefei
of
the
and
in
research
macromolecular
drug
than
development
Scan the QR code to read on your phone
We could not find any corresponding parameters, please add them to the properties table
There is currently no content to display
Please add data record on website background.

Copyright: © 2021 Biotheus, Inc.     粤ICP备2021122492号      Powered by www.300.cn